Mission

To offer lifesaving therapeutic alternatives to cancer patients that improve their survivorship outcome and quality of life. Dynamiko Pharmaceutics focuses on the discovery and development of selective and targeted drugs that benefit patients, clinicians, and stakeholders.

  • Founder and President

    Michelle M. Martinez, PhD has more than 15 years’ experience in the research of natural products isolated from Ganoderma lucidum against aggressive breast cancer models. Her multi-disciplinary background covers animal science, nutritional genomics, molecular and cellular cognition cancer biology, and cellular and molecular biology. She is an associate professor in the Department of Biochemistry at Universidad Central del Caribe School of Medicine (UCC) in Puerto Rico. She has contributed to the field with multiple research publications and has received multiple awards and honors in her career. Dr. Martínez received her PhD from Michigan State University and completed her two postdoctoral fellowships at the University of Puerto Rico and UCC.

  • Co-founder and Vice-president

    Fatima Rivas, PhD is an assistant professor in the Department of Chemistry at Louisiana State University. She earned a doctoral degree in Organic Chemistry from University of California San Diego, and conducted postdoctoral work at the Scripps Research Institute in La Jolla, CA. Her expertise is on the synthesis and modification of natural products to improve their biological profiles. She led her research group at St Jude Children’s Research Hospital for 10 years working on pediatric malignancies. The Rivas Research group discovers and uses natural products as chemical probes to identify novel biological targets in drug resistant cancers. She drives natural product screening campaigns to generate new lead matter and obtains insightful information against therapeutically relevant biological targets.